Introduction
============

Gastric cancer (GC) represents the fourth most common malignant neoplasm and the second leading cause of cancer-related death worldwide. More than 40% of all GC cases diagnosed annually occur in China, of whom almost 50% are diagnosed at an advanced stage and cannot be cured. Treatment of advanced GC is challenging. Epirubicin, cisplatin, and fluorouracil (ECF) and its modified regimens, such as EOF (epirubicin, oxaliplatin, and fluorouracil) and EOX (epirubicin, oxaliplatin, and capecitabine), are widely used to treat GC patients based on the results of phase III clinical trials. However, although these regimens are common first-line treatments, their response rates remain \<50%. Biomarkers able to predict chemotherapeutic efficacy are therefore urgently needed.

Both membrane transporters and metabolic enzymes affect cytotoxic-drug metabolism. Solute carrier (SLC) superfamily proteins and ATP-binding cassette (ABC)-transporters are vital membrane transporters. *SLCO1B1* encodes the transporter protein, organic anion-transporting polypeptide-1 (OATP1B1), which mediates liver uptake of a wide variety of drugs, and its role in the efficacy of cytotoxic drugs, including 5-fluorouracil (5FU) ([@b1-ol-0-0-9147],[@b2-ol-0-0-9147]), methotrexate (MTX) ([@b3-ol-0-0-9147]--[@b5-ol-0-0-9147]), irinotecan ([@b6-ol-0-0-9147],[@b7-ol-0-0-9147]), and paclitaxel ([@b8-ol-0-0-9147]) has been widely reported. MTX was the first cytotoxic drug reported to be associated with *SLCO1B1*, and *SLCO1B1* SNPs were shown to affect MTX pharmacokinetics in children with acute lymphoblastic leukemia, particularly in terms of deposition and toxicity ([@b5-ol-0-0-9147]). These findings have been validated in several later studies ([@b9-ol-0-0-9147]--[@b11-ol-0-0-9147]). The breast cancer resistance protein (BCRP/ABCG2) has been reported to affect drug resistance in many cancer types, including colorectal cancer, lymphoblastic leukemia, and breast cancer ([@b12-ol-0-0-9147]--[@b15-ol-0-0-9147]), and ABCG2 polymorphisms are prognostic factors in breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy ([@b16-ol-0-0-9147]). Expression levels of glucose transporters (GLUT/SLC1A) were also shown to be related to response to 5FU chemotherapy in GC cells ([@b17-ol-0-0-9147]), and glucose transporters were reported to be independent prognostic factors in patients with GC ([@b18-ol-0-0-9147],[@b19-ol-0-0-9147]).

Among metabolic enzymes, the cytochrome-P450 (CYP) enzyme family plays an important role in the metabolism of various anticancer drugs ([@b20-ol-0-0-9147]). Several studies have shown that SNPs in *CYP2C9* influence disease-free survival in breast cancer patients treated with tamoxifen ([@b21-ol-0-0-9147],[@b22-ol-0-0-9147]). Moreover, *CYP2C9* polymorphism was related to response to fluorouracil-based neoadjuvant chemotherapy in breast cancer ([@b23-ol-0-0-9147]). CYP2C19 is involved in the metabolism of cyclophosphamide ([@b24-ol-0-0-9147],[@b25-ol-0-0-9147]) and tamoxifen ([@b26-ol-0-0-9147],[@b27-ol-0-0-9147]), and P450 enzymes in human liver microsomes, including CYP1A2 have also been reported to catalyze tegafur into 5FU ([@b28-ol-0-0-9147]).

Metabolism-related genes, including *SLCO1B1, ABCG2, SLC2A9, CYP2C9, CYP2C19*, and *CYP1A2*, might thus influence the efficacy of EOF regimens. In the present study, we investigated the associations between metabolism-related genes and the clinical outcomes of GC patients treated with first-line EOF regimens, in terms of disease-control rate (DCR), progression-free survival (PFS), and overall survival (OS).

Materials and methods
=====================

### Study population

This retrospective study enrolled 108 consecutive Chinese Han patients with metastatic GC (MGC) treated with EOF regimens as first-line chemotherapy at Fudan University Shanghai Cancer Center (Shanghai, China) between May 2009 and June 2012. Their diagnoses were pathologically confirmed as gastric adenocarcinoma. The study was approved by the Ethics Committee of Fudan University Shanghai Cancer and complied with the principles of the Helsinki Accord. This was a retrospective study and patient consent was therefore deemed unnecessary. However, blood samples were collected from all subjects before treatment, with patient consent, and stored in the tissue bank at Fudan University Shanghai Cancer Center.

### Treatment

All patients in this study were treated with first-line chemotherapy using an EOF regimen, consisting of epirubicin infusion (50 mg/m2) combined with an intravenous infusion of oxaliplatin (130 mg/m2) for 2 h on day 1, following a 24-h continuous infusion of 5FU (375--425 mg/m2/day) for 5 days, over a 21-day treatment cycle. Tumor responses were evaluated every 6 weeks in accordance to the Response Evaluation Criteria in Solid Tumors 1.0 (RECIST 1.0). Treatment was terminated in the event of disease progression or unacceptable toxicity. If the lesions continued to shrink after six cycles, with no unacceptable toxicity, a further one or two EOF cycles were recommended; otherwise, oral FU was recommended as follow-up treatment.

### SNP selection and genotyping

We selected and genotyped 13 drug-metabolism-related genetic polymorphisms located at *SLCO1B1* (rs4149056), *SLC2A9* (rs16890979, rs6449213, rs734553), *ABCG2* (rs2231142), *CYP2C9* (rs1057910, rs1799853), *CYP2C19* (rs72552267, rs28399504, rs56337013, rs41291556), and *CYP1A2* (rs12720461, rs56107638), respectively, from the Hapmap project ([www.hapmap.org](www.hapmap.org)) and dbSNP databases ([www.ncbi.nlm.nih.gov/SLP](www.ncbi.nlm.nih.gov/SLP)) ([Table I](#tI-ol-0-0-9147){ref-type="table"}). Genomic DNA was extracted from venous blood leukocytes using a standard phenol-chloroform method. The selected SNPs were genotyped using the TaqMan assay method and an ABI 7900 DNA detection system (Applied Biosystems, Foster City, CA, USA). All the probes and primers were designed using the Assay-on-Design service from Applied Biosystems. The experiments were repeated for 15% of the samples. The genotype error rate was \<0.03%.

### Statistical analysis

The allelic and genotypic distributions and Hardy-Weinberg equilibrium were analyzed using the online analysis tool, SHEsis. Differences in clinical characteristics among the 108 GC patients were analyzed by χ2 tests, and differences in allelic and genotypic frequencies between the controlled-disease and progressive-disease groups were compared with χ2 or Fisher\'s exact probability tests. Genetic power was calculated using the G\*Power program ([@b29-ol-0-0-9147]). Survival curves were analyzed using the Kaplan-Meier method. Differences in PFS and OS between genotype groups were estimated by log-rank tests. Multivariate analysis of prognostic predictors was carried out using a Cox proportional hazards model. A two-sided P-value \<0.05 was considered significant. P-values for association analysis were corrected by a false-discovery rate (FDR) procedure ([@b30-ol-0-0-9147]). To be detailed, FDR p=p\*n/a. In this formula, n is the number of SNPs in the same gene, and a is the rank of the P-value among the SNPs in the same gene.

Results
=======

### Patient characteristics

Most of the 108 GC patients enrolled in the study had ≥3 tumor sites, with the most common metastatic organs being the liver and retroperitoneal lymph nodes. Among the clinicopathological features, liver metastasis and pleural effusion were significantly associated with OS, whereas histological grade, number of tumor sites, retroperitoneal lymph node involvement, and ascites were significantly associated with PFS ([Table II](#tII-ol-0-0-9147){ref-type="table"}).

The responses to EOF chemotherapy were CR, n=1; PR, n=41; SD, n=47; and PD, n=19. The 89 patients with CR, PR, or SD were classified as the disease-control group and the 19 patients with PD were classified as the disease-progression group.

### Genotype frequency and disease control

There was no significant relationship between genotype frequency and disease-control rate for any of the 13 SNPs analyzed in the present study ([Table III](#tIII-ol-0-0-9147){ref-type="table"}). There was only one genotype distribution each for *CYP2C19* (rs72552267, rs28399504, rs56337013, rs41291556) and *CYP1A2* (rs12720461, rs56107638) in the 108 patients (data not shown).

### Genotype frequency and survival analysis

Univariate analysis of the 13 SNPs in relation to survival ([Table IV](#tIV-ol-0-0-9147){ref-type="table"}) showed that patients with *SLCO1B1* rs4149056 CC and CT genotypes had significantly longer median OS than patients with the TT genotype (565 vs. 312 days, log-rank P=0.039; [Fig. 1](#f1-ol-0-0-9147){ref-type="fig"}). However, there was no significant association between PFS and *SLCO1B1* rs4149056 (log-rank P=0.956; [Fig. 2](#f2-ol-0-0-9147){ref-type="fig"}), or between any of the other 12 SNPs and OS or PFS ([Table IV](#tIV-ol-0-0-9147){ref-type="table"}).

### Multivariate PFS and OS analysis with cox regression

Multivariate analysis showed that *SLCO1B1* rs4149056 genotype, liver metastasis, ascites, pleural effusion, and number of tumor sites were significantly or borderline-significantly associated with OS ([Table V](#tV-ol-0-0-9147){ref-type="table"}). In addition, histological grade, retroperitoneal lymph node involvement, ascites, pleural effusion, and number of tumor sites were significantly or borderline-significantly associated with PFS. All the above factors were included in a stepwise multivariate Cox regression model, which confirmed that *SLCO1B1* rs4149056 was an independent prognostic factor for shorter OS (P=0.014), but not PFS (P=0.533).

### Linkage disequilibrium analysis

We analyzed linkage disequilibrium (LD) for the SLC2A9 and CYP2C9 SNPs in AGC patients HaploView software. The *SLC2A9* SNPs rs16890979 and rs6449213 (D\'=1.000, r2=0.796), SLC2A9 SNPs rs16890979 and rs734553 (D\'=1.000, r2=1.000) and *SLC2A9 SNPs rs6449213* and *rs734553* (D\'=1.000, r2=0.796) all showed strong LD ([Fig. 3A](#f3-ol-0-0-9147){ref-type="fig"}). *CYP2C9* SNPs rs1057910 and rs1799853 showed no LD (D\'=1.000, r2=0.000) ([Fig. 3B](#f3-ol-0-0-9147){ref-type="fig"}). Since the most samples showed the same allele and only less than 5 samples showed different allele in the SCL2A9 SNPs, linkage disequilibrium and haplotype analysis cannot find clinically meaningful result.

Discussion
==========

We investigated the association between SNPs of metabolism-related genes and chemotherapy response in patients with MGC. Patients with *SLCO1B1* rs4149056 CC and CT genotypes had longer OS than patients with TT genotype (312 vs. 565 days, P=0.039), and *SLCO1B1* rs4149056 TT was confirmed as an independent prognostic factor for shorter OS in GC patients treated with EOF by Cox regression analysis (hazard ratio: 2.565, 95% confidence interval: 1.215--5.415, P=0.014).

*SLCO1B1* encodes the SLC family member OATP1B1, which is highly expressed in hepatocytes and associated with hepatic drug uptake and elimination ([@b31-ol-0-0-9147]). Among single-nucleotide variants of *SLCO1B1*, c.521T\>C rs4149056 had the greatest effect on OATP1B1 activity in this study. *SLCO1B1* c.521T\>C decreases OATP1B1 transporting activity, thus increasing plasma concentrations of drugs, including cytotoxic drugs. *SLCO1B1* rs4149056 has been significantly associated with exposure to SN-38, the active metabolite of irinotecan ([@b7-ol-0-0-9147]). In another study, OATP1B1 was responsible for SN-38 uptake from plasma into hepatocytes ([@b6-ol-0-0-9147]). Innocenti *et al* also revealed that *SLCO1B1* rs4149056 increased patient exposure to CPT-11 and was associated with an increased risk of severe neutropenia ([@b6-ol-0-0-9147]). OATP1B1 was shown to transport paclitaxel in an *in vitro* ovarian cancer study, implying that it contributed to the disposition of paclitaxel ([@b8-ol-0-0-9147]). Huang *et al* reported that another *SLCO1B1* variant, rs2306283, was an independent prognostic factor for longer PFS in patients with metastatic colorectal cancer treated with a fluoropyrimidine plus irinotecan ([@b1-ol-0-0-9147]). Overall, these studies suggest that *SLCO1B1* affects the metabolism of fluoropyrimidines, CPT-11, and docetaxel, thus influencing their chemotherapeutic efficacy, consistent with the results of the current study.

To the best of our knowledge, the present study provides the first evidence for an association between *SLCO1B1* and GC. A literature search of MEDLINE via PubMed found no similar reports with respect to the efficacy of first-line chemotherapy, GC risk, or prognosis.

Notably, although we identified *SLCO1B1* rs4149056 as a prognostic factor for OS in MGC patients treated with first-line EOF, we failed to detect any correlation between *SLCO1B1* rs4149056 and PFS. There are two possible reasons for this apparent discrepancy. First, *SLCO1B1* rs4149056 may only be a prognostic factor in GC patients, and may not affect the short-term efficacy of first-line chemotherapy. Second, CPT-11 or paclitaxel were administered as the main second- or third-line chemotherapy regimens in the present study; as noted above, *SLCO1B1* rs4149056 has been associated with the metabolism of CPT-11 and paclitaxel, and rs4149056 may thus affect OS by influencing the efficacy of the second- or third-line regimens.

In our study, *ABCG2* (BCRP2) C421A rs2231142 was borderline-significantly associated with PFS (P=0.083), though multivariate analysis did not identify it as an independent predictor in GC patients treated with EOF regimen. However, several previous studies reported significant relationships between *ABCG2* (BCRP2) C421A rs2231142 and the toxicity or efficacy of oxaliplatin or anthracyclines. Custodio *et al* revealed that *ABCG2* rs3114018 was associated with oxaliplatin-induced peripheral neuropathy in patients with stage II--III colon cancer ([@b32-ol-0-0-9147]), while breast cancer patients with an *ABCG2* rs2231142 A allele reportedly showed better responses to anthracycline-based neoadjuvant chemotherapy ([@b16-ol-0-0-9147]). Ghafouri *et al* also showed that the *ABCG2* rs22311442 A allele was associated with stronger responses to anthracyclines and paclitaxel ([@b33-ol-0-0-9147]). Overall, these three studies indicated that patients with an *ABCG2* rs22311442 A allele showed better responses to anthracyclines and paclitaxel. Although the current univariate analysis failed to find an association between *ABCG* rs22311442 and PFS, there was a nonsignificant tendency towards longer PFS among rs22311442 AA/AC compared with rs22311442 CC patients. There are three possible reasons for this apparent discrepancy. First, it is possible that the sample-size was too small to demonstrate any significant difference between the survival trends of patients with rs22311442 A and C alleles, respectively. Second, the previous studies involved patients with colon cancer or breast cancer, rather than GC, and the results may thus have been affected by this tumor heterogeneity. Third, the EOF regimen contains epirubicin, oxaliplatin, and 5FU. Custodio showed an association between *ABCG2* rs22311442 and oxaliplatin toxicity rather than oxaliplatin response, which differed from our current study.

Evidence suggests that some CYP450 enzyme family members affect 5FU metabolism ([@b34-ol-0-0-9147]--[@b37-ol-0-0-9147]). 5FU was reported to reduce the ability to metabolize a CYP2C9 probe drug ([@b38-ol-0-0-9147]). Moreover, several studies have indicated that 5FU can down-regulate the expression of CYP enzymes, including CYP2C9 and CYP2C19 ([@b39-ol-0-0-9147],[@b40-ol-0-0-9147]). However, although CYP2C9 and CYP2C19 have been shown to influence 5FU metabolism *in vitro*, these results have not yet been verified in clinical studies. Furthermore, no studies have reported on the relationship between 5FU efficacy and SNPs in *CYP2C9* or *CYP2C19*. Our results showed that all 108 blood samples had the same genotypic distributions of *CYP2C9* and *CYP2C19* SNPs, except for *CYP2C9* rs1057910, which was not significantly associated with PFS or OS. The roles of CYP2C9 and CYP2C19 in 5FU metabolism thus currently remain unclear.

There were several limitations to the present study. First, we only analyzed some of the genes related to the CYP, SLC, and ABC families, and any associations between the remaining untested genes and GC remain unknown. Second, we only detected selected polymorphisms for each target agent, and other potentially related polymorphisms may have been missed. Third, the sample size was relatively small. The conclusions of this study therefore require verification in further studies.

In conclusion, the present study identified an association between the *SLCO1B1* rs4149056 SNP and clinical outcomes of MGC patients treated with EOF chemotherapy. The resulting risk model successfully divided patients into low-risk and high-risk groups, with a significant difference in OS, but not PFS. *SLCO1B1* rs4149056 is therefore a prognostic, but not a predictive factor in MGC patients treated with EOF. Further studies are required to validate our results and to detect other potential prognostic sites in *SLCO1B1*.
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###### 

SNPs in the SLCO1B1, SLC2A9, SLC17A1, ABCG2, CYP2C9, CYP2C19 and CYP1A2 genes analyzed in the article.

  Gene      SNP ID       Chromosome    Function       Allele   HWE test P-value
  --------- ------------ ------------- -------------- -------- ------------------
  SLCO1B1   rs4149056    12:21178615   Missense       T/C      0.608
  SLC2A9    rs16890979   4:9920543     Missense       C/T      0.903
  SLC2A9    rs6449213    4:9992591     Intron         C/T      0.903
  SLC2A9    rs734553     4:9921380     Intron         A/C      0.903
  ABGC2     rs2231142    4:88131171    Missense       A/C      0.047
  CYP2C9    rs1057910    10:94981296   Missense       A/C      0.808
  CYP2C9    rs1799853    10:94942290   Missense       C/T      1.000
  CYP2C19   rs72552267   10:94775453   Missense       A/G      1.000
  CYP2C19   rs28399504   10:94762706   Missense       A/G/T    1.000
  CTP2C19   rs56337013   10:94852738   Missense       C/T      1.000
  CYP2C19   rs41291556   10:94775416   Missense       C/T      1.000
  CYP1A2    rs12720461   15:74749010   Intron         C/T      1.000
  CYP1A2    rs56107638   15:74753271   Splice donor   A/C/G    1.000

HWE, hardy-weinberg equilibrium; SNP, single nucleotide polymorphism.

###### 

Associations between patient characteristics and survival.

  Characteristics              Number of patients (%)   Median OS   P-value   Median PFS   P-value
  ---------------------------- ------------------------ ----------- --------- ------------ ---------
  Age (years)                                                                              
    ≤60                        80 (74.1)                465         0.916     159          0.176
    \>60                       28 (25.9)                403                   187          
  Sex                                                                                      
    Male                       64 (59.3)                534         0.359     166          0.163
    Female                     44 (40.7)                372                   182          
  ECOG performance status                                                                  
    0                          14 (13.0)                704         0.153     240          0.768
    1                          89 (82.4)                367                   167          
    2                          5 (4.6)                  299                   237          
  Histological grade                                                                       
    Moderate and high          13 (12.0)                403         0.226     156          0.004
    Low/undifferentiated       66 (61.2)                875                   380          
    Unclassified               29 (26.8)                367                   180          
  Number of tumor sites                                                                    
    1                          5 (4.6)                  984         0.076     545          0.038
    2                          8 (7.4)                  570                   411          
    ≥3                         95 (88.0)                372                   167          
  Metastasis sites                                                                         
    Liver                                                                                  
      Yes                      36 (33.3)                281         0.004     169          0.232
      No                       72 (66.7)                570                   178          
    Lung                                                                                   
      Yes                      7 (6.5)                  252         0.997     169          0.885
      No                       101 (93.5)               444                   187          
  Retroperitoneal lymph node                                                               
    Yes                        45                       372         0.710     156          0.033
    No                         63                       534                   192          
  Ascites                                                                                  
    Yes                        32                       312         0.101     126          0.015
    No                         76                       534                   192          
  Pleural effusion                                                                         
    Yes                        9                        211         0.001     144          0.054
    No                         99                       475                   178          

Log-rank test. PFS, progression free survival; OS, overall survival.

###### 

Allelic and genotypic distribution of the 15 SNPs in the disease control (CR, PR and SD) and the disease progressive (PD) to chemotherapy.

  Gene      SNP          Allele frequency   Chi2 value    P-value   Odds ratio 95% CI   Genotype frequency      P-value                                
  --------- ------------ ------------------ ------------- --------- ------------------- ----------------------- ------------ ------------ ------------ -------
  SLCO1B1   Rs4149056    C                  T                                                                   CC           CT           TT           
            CR+PR+SD     4 (0.105)          34 (0.895)    0.372     0.541               0.705 (0.229--2.168)    0 (0.000)    4 (0.211)    15 (0.789)   0.700
            PD           24 (0.143)         144 (0.857)                                                                                                
  SLC2A9    rs16890979   C                  T                                                                   CC           CT                        
            CR+PR+SD     35 (0.972)         1 (0.028)     0.185     0.666               0.606 (0.061--6.006)    17 (0.944)   1 (0.056)                 0.663
            PD           173 (0.983)        3 (0.017)                                                           85 (0.966)   3 (0.034)                 
  SLC2A9    rs6449213    C                  T                                                                   CT           TT                        
            CR+PR+SD     1 (0.028)          35 (0.972)    0.036     0.847               1.242 (0.134--11.457)   1 (0.056)    17 (0.944)                0.845
            PD           4 (0.022)          174 (0.978)                                                         4 (0.045)    85 (0.955)                
  SLC2A9    rs734553     A                  C                                                                   AA           AC                        
            CR+PR+SD     35 (0.972)         1 (0.028)     0.168     0.681               0.621 (0.062--6.149)    17 (0.944)   1 (0.056)                 0.678
            PD           169 (0.983)        3 (0.017)                                                           83 (0.965)   3 (0.035)                 
  ABGC2     Rs2231142    A                  C                                                                   AA           AC           CC           
            CR+PR+SD     7 (0.194)          29 (0.806)    2.081     0.149               0.525 (0.217--1.272)    2 (0.111)    3 (0.167)    13 (0.722)   0.175
            PD           56 (0.315)         122 (0.685)                                                         11 (0.124)   34 (0.382)   44 (0.494)   
  CYP2C9    Rs1057910    A                  C                                                                   AA           AC                        
            CR+PR+SD     36 (0.947)         2 (0.053)     2.952     0.085               0.204 (0.027--1.500)    17 (0.895)   2 (0.105)                 0.082
            PD           176 (0.989)        2 (0.011)                                                           87 (0.978)   2 (0.022)                 
  CYP2C9    rs1799853    C                  T                                                                   CC           CT                        
            CR+PR+SD     36 (1.000)         0 (0.000)     0.203     0.652                                       18 (1.000)   0 (0.000)                 0.651
            PD           177 (0.994)        1 (0.006)                                                           88 (0.989)   1 (0.011)                 

χ2 test. SNP, single nucleotide polymorphism.

###### 

Univariate survival analysis of SNPs and overall survival/progression free survival time.

  SNPs                Median OS   95% CI          P-value   Median PFS   95% CI         P-value
  ------------------- ----------- --------------- --------- ------------ -------------- ---------
  SLCO1B1 rs4149056                                                                     
    TT                312.0       178.0--445.9    0.039     173.0        142.7--203.2   0.760
    CC+CT             565.0       108.9--1021.0             179.0        157.6--200.3   
  SLC2A9 rs16890979                                                                     
    CC                465.0       303.1--626.8    0.301     176.0        156.7--195.2   0.427
    TC                189.0       0.0--383.6                162.0        0.0--353.6     
  SLC2A9 rs6449213                                                                      
    CT                265.0       94.0--435.9     0.161     162.0        55.8--268.1    0.257
    TT                465.0       304.2--625.7              176.0        161.4--190.5   
  SLC2A9 rs734553                                                                       
    AA                444.0       307.7--580.2    0.282     173.0        154.2--191.7   0.489
    CA                189.0       0.0--383.6                162.0        0-353.6        
  ABGC2 rs2231142                                                                       
    CC                444.0       293.2--594.7    0.750     167.0        144.1--189.8   0.083
    AA+CA             475.0       128.5--821.4              182.0        138.1--225.8   
  CYP2C9 rs1057910                                                                      
    AA                444.0       289.8--598.1    0.382     176          156.8--195.1   0.311
    CA                295.0       0.0--727.6                41           0.0--202.7     
  CYP2C9 rs1799853                                                                      
    CC                465.0       272.9--657.0    0.711     173.0        153.6--192.3   0.750
    CT                444.0       --                        178.0        --             

Log-rank test. PFS, progression-free survival; OS, overall survival; HR, hazards ratio; CI, confidence interval; SNP, single nucleotide polymorphism.

###### 

Multi-factorial analysis of prognostic factors for PFS and OS.

                     OS      PFS                            
  ------------------ ------- ---------------------- ------- ----------------------
  rs4149056 TT       0.014   2.565 (1.215--5.415)   --      --
  Grade              --      --                     0.221   --
  PLN                --      --                     0.003   2.041 (1.271--3.278)
  Ascites            0.050   0.508 (0.258--0.999)   0.436   0.818 (0.494--1.355)
  Pleural effusion   0.016   0.363 (0.159--0.827)   0.071   0.497 (0.232--1.061)
  Liver              0.002   0.372 (0.179--0.703)   --      --
  Number of sites    --      --                     0.200   --
  rs2231142 CC       --      --                     0.342   1.239 (0.796--1.929)

Cox proportional hazards model. PFS, progression-free survival; OS, overall survival; HR, hazards ratio; CI, confidence interval; PLN, retroperitoneal lymph node.
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